{"id":"miloxacin","rwe":[{"pmid":"26711252","year":"2016","title":"Interspecies scaling of excretory amounts using allometry - retrospective analysis with rifapentine, aztreonam, carumonam, pefloxacin, miloxacin, trovafloxacin, doripenem, imipenem, cefozopran, ceftazidime, linezolid for urinary excretion and rifapentine, cabotegravir, and dolutegravir for fecal excretion.","finding":"","journal":"Xenobiotica; the fate of foreign compounds in biological systems","studyType":"Clinical Study"},{"pmid":"8832440","year":"1996","title":"High-performance liquid chromatographic method for the rapid and simultaneous determination of sulfamonomethoxine, miloxacin and oxolinic acid in serum and muscle of cultured fish.","finding":"","journal":"Journal of chromatography. B, Biomedical applications","studyType":"Clinical Study"},{"pmid":"2907467","year":"1988","title":"Structure-tissue distribution relationship based on physiological pharmacokinetics for NY-198, a new antimicrobial agent, and the related pyridonecarboxylic acids.","finding":"","journal":"Drug metabolism and disposition: the biological fate of chemicals","studyType":"Clinical Study"},{"pmid":"6801153","year":"1981","title":"[Clinical studies of miloxacin for acute intestinitis (author's transl)].","finding":"","journal":"Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases","studyType":"Clinical Study"},{"pmid":"7328756","year":"1981","title":"[Chemotherapy on the biliary tract infections. XIII. Miloxacin, a novel chemotherapeutic agent, its excretion into bile and clinical effect on the biliary tract infections (author's transl)].","finding":"","journal":"The Japanese journal of antibiotics","studyType":"Clinical Study"}],"tags":[{"label":"miloxacin","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"fuldazin","offLabel":[],"synonyms":["miloxacin","fuldazin"],"timeline":[],"approvals":[],"brandName":"Fuldazin","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"miloxacin","explanation":"Think of it like a copy machine. Bacteria need to make copies of their DNA to grow and multiply. Miloxacin blocks the copy machine, preventing the bacteria from making new copies of their DNA and ultimately stopping them from growing and multiplying.","oneSentence":"Miloxacin works by inhibiting bacterial DNA replication and transcription.","technicalDetail":"Miloxacin is a quinolone antibiotic that exerts its antibacterial effects by inhibiting DNA gyrase and topoisomerase IV, enzymes critical for bacterial DNA replication and transcription."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3360","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=MILOXACIN","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T12:45:31.677415","biosimilars":[],"competitors":[],"genericName":"miloxacin","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"VM4W7043SN","CHEBI":"CHEBI:135084","INN_ID":"4524","UMLSCUI":"C0066553","ChEMBL_ID":"CHEMBL339309","KEGG_DRUG":"D02303","PUBCHEM_CID":"37614","MESH_SUPPLEMENTAL_RECORD_UI":"C023981"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":12,"therapeuticAreas":["Infectious Disease"],"biosimilarFilings":[],"recentPublications":[{"date":"2016 Sep","pmid":"26711252","title":"Interspecies scaling of excretory amounts using allometry - retrospective analysis with rifapentine, aztreonam, carumonam, pefloxacin, miloxacin, trovafloxacin, doripenem, imipenem, cefozopran, ceftazidime, linezolid for urinary excretion and rifapentine, cabotegravir, and dolutegravir for fecal excretion.","journal":"Xenobiotica; the fate of foreign compounds in biological systems"},{"date":"1996 Jun 28","pmid":"8832440","title":"High-performance liquid chromatographic method for the rapid and simultaneous determination of sulfamonomethoxine, miloxacin and oxolinic acid in serum and muscle of cultured fish.","journal":"Journal of chromatography. B, Biomedical applications"},{"date":"1988 Nov-Dec","pmid":"2907467","title":"Structure-tissue distribution relationship based on physiological pharmacokinetics for NY-198, a new antimicrobial agent, and the related pyridonecarboxylic acids.","journal":"Drug metabolism and disposition: the biological fate of chemicals"},{"date":"1981 Nov","pmid":"6801153","title":"[Clinical studies of miloxacin for acute intestinitis (author's transl)].","journal":"Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases"},{"date":"1981 Sep","pmid":"7328756","title":"[Chemotherapy on the biliary tract infections. XIII. Miloxacin, a novel chemotherapeutic agent, its excretion into bile and clinical effect on the biliary tract infections (author's transl)].","journal":"The Japanese journal of antibiotics"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fuldazin, also known as Miloxacin, is a small molecule drug in the miloxacin class. Its exact target is unknown, but it is believed to work by inhibiting bacterial growth. Miloxacin is not FDA-approved for any indications, and its commercial status, patent status, and availability of generic manufacturers are also unknown. Further research is needed to determine its safety and efficacy. As a result, it is not currently available for clinical use.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}